Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK | Zendy

Jürgen K. Rockstroh | Zendy; Jeffrey L. Lennox | Zendy; Edwin DeJesus | Zendy; Michael S. Saag | Zendy; Adriano Lazzarin | Zendy; Hong Wan | Zendy; Monica L. Walker | Zendy; Xia Xu | Zendy; Jing Zhao | Zendy; Hedy Teppler | Zendy; Mark J. DiNubile | Zendy; Anthony Rodgers | Zendy; Bach-Yen Nguyen | Zendy; Randi Y. Leavitt | Zendy; Peter Sklar | Zendy

Open Access

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

Author(s) -

Jürgen K. Rockstroh,

Jeffrey L. Lennox,

Edwin DeJesus,

Michael S. Saag,

Adriano Lazzarin,

Hong Wan,

Monica L. Walker,

Xia Xu,

Jing Zhao,

Hedy Teppler,

Mark J. DiNubile,

Anthony Rodgers,

Bach-Yen Nguyen,

Randi Y. Leavitt,

Peter Sklar

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir510

Subject(s) - efavirenz , raltegravir , emtricitabine , medicine , virology , regimen , human immunodeficiency virus (hiv) , integrase inhibitor , antiretroviral treatment , antiretroviral therapy , viral load

We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part of a combination regimen in the ongoing STARTMRK study of treatment-naive patients infected with human immunodeficiency virus (HIV).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research